Erasca, Inc Investor Event Transcript, Nov 18, 2026
Erasca, Inc. (ERAS)
The CEO said the 32 milligram cohort had about seven patients in July and is guided to more than double that. He said 32 milligrams did seem like the most promising dose based on the July data. The CFO said a collaboration with BMS for NABLI metastat, a PRMT5 inhibitor, was announced the previous evening. AI summary
Conference Transcript - ERAS 2026-11-18
David Chacko, CFO
All right.
Amine Makarim, Analyst — Jefferies
Thank you, everyone, for joining us. I'm Amin Makarim, one of the biotech analysts here at Jefferies. I'm happy to introduce and welcome Jonathan Lim, CEO, and David Chagos, CFO, CEO of URASCA. This is a Fireside Chat, and thank you for joining us.
Jonathan Lim, CEO
Thank you for having us here.
Amine Makarim, Analyst — Jefferies
Yeah, of course. And so for those who may be new to this story, can you provide a one-minute intro to URASCA?
Jonathan Lim, CEO
Yeah, Erasca is a company whose mission is to erase cancer and eradicate RAS-driven cancer. Our pipeline consists of two RAS-targeting agents. The lead program is ERAS-15, which is a pan-RAS molecular glue. The second program is ERAS-4001, which is a pan-K-RAS molecule that spares H and N-RAS. And both of these are in phase one studies. So ERAS-15 is in a Phase I U.S. trial called AURORAS-1, and I know we'll be talking a lot more about that. We're excited to have an oral presentation at the triple meeting in Barcelona in two days to provide an update on that molecule. And then ERAS-4001 is in the Borealis-1 dose escalation trial.
Amine Makarim, Analyst — Jefferies
All right, thanks. So the most immediate topic, obviously, triple meeting. In the July update, you had around 15 PDEC patients at the two higher doses, 24 and 32 milligram. And I think you said you're expecting at least twice the number of patients. Just wanted to know how many valuable patients will be at 32 milligram. Is this 2x related to these two higher doses? And also, uh... Will you break out the patients who are second-line PDAC versus third-line PDAC in terms of efficacy and safety?
Jonathan Lim, CEO
Yeah, so just backing up, the pharmacologically active dose for ERAS-15 is between 16 to 32 milligrams. But in our July data set, to your point, there seemed to be a striking dose response. So for instance, the response rate observed at 32 milligrams was substantially higher than that observed at less than 32 milligrams. So I think that's probably the cohort that we're going to want to focus on is 32 milligrams versus below 32. And while in July, there were only about seven patients, we are guiding to more than double that. So let's say, for instance, if there's 15 to 20 patients at 32 milligrams, well, now you have a critical mass of data where you can start separating out allele-specific activity. Not that there's going to be tons of patients for each allele, but at least you'll start to have more meaningful observations in terms of the number of patients where you can start to see what is the activity against G12D, What's the activity against G12V, G12R?
Amine Makarim, Analyst — Jefferies
All right, and I think you have a bar of ORR for like 40%-ish. Is that for the highest dose, the 32 milligram, or like the 24 to 32 milligram, both of them? How should we think about this bar?
Jonathan Lim, CEO
Yeah, I think backing up, the bar that we set was wanting to show 10 percentage points of ORR differentiation in pancreatic and lung. This was in April. We had sort of a scorecard that we put out, and I think what you want to do is put your best foot forward, especially in a disease state like pancreatic cancer, where we've seen from other molecules in the field that you want to really go with as high a dose as you possibly can because pancreatic cancer is such a difficult disease to treat. And actually, if you look at the example of Dirac's, they do have a higher dose in pancreatic than what has been selected for non-small cell lung cancer, for instance. So I think for us, based on the July data, if you had to pick then, based on small data, 32 milligrams did seem like the most promising dose. So I think for us it's really about the benefit risk that we see at different doses. And if the key is that 32 milligrams is also safe and tolerable with less dose interruptions and dose reductions and dose discontinuations, then that could be the most promising go-forward dose. So I think that answers your question. But, yeah, feel free to probe for that.
Amine Makarim, Analyst — Jefferies
Of course. So, I'm wondering what are we going to see in terms of durability in this patient population, the follow-up, what would be the median follow-up of this patient goal. Of course, you added new patients compared to the previous readout. How should we think about… The, let's say, the PFS or duration of response, anything that we can probably see at the triple?
Jonathan Lim, CEO
Well, so for 32 milligrams, if there were seven patients that we reported in July, and then I'm telling you that there's going to be more than double that, by implication, a lot of the, it means a lot of the patients would have been recently enrolled. So we certainly will follow all of the patients that we've reported on historically, as well as the new patients. And so we'll show the swimmer plots. And you can, you know, on one extreme, if every patient comes off therapy, then it's very easy to report what the durability is. But if every patient stays on therapy, then you may not have mature enough data for PFS or much less, you know, landmark PFS. And then the reality might be somewhere in between. So I think the main thing to look at is the swimmer plots, looking at how many patients remain on treatment, what are the kinetics of response? Are you having to wait until the second, third, or later, you know, cycle for scan for a patient to respond, or do they respond early? So I think based on the data set on Friday, we hope for interpretability to be looked at through all of those lenses.
Amine Makarim, Analyst — Jefferies
All right. And just touching on G12D population, because there has been some discussions recently about that, you had around, I think, 50% response rate in G12D across the two higher doses in the last cuts. Dioxin-Racid showed, I think, 20, 24%. Do you expect to still see a higher response rate in this population? And, uh... Do you think this has some sort of a biological rationale or a small end can affect this conclusion? What's your take there?
Jonathan Lim, CEO
Well, we'll be transparent about it in terms of these are the data across all the different alleles, and then we'll have to look at sort of two main areas that can impact response. So one is line of treatment, where I think Diracxon RASIV has shown a very promising objective response rate of 32% in second line. In our July data set, 75% of our patients were treated in the third line plus setting, so they were pretty heavily pretreated. And then in terms of the mutational breakout, I think at the time we had reported a higher proportion of G12R, which tends to be a less sensitive mutation. G12V is probably the most sensitive to pan-ras inhibition, and then G12D is somewhere in between. I know that if we don't break it out, you will. And so, you know, we'll be very transparent about what the allele frequency is, as well as what the response rates are against the different G12X mutations. I would say that if our response rate in G12D, which you mentioned, you know, a lot of investors have looked at the July data set and done their own math where across a dose range they've seen that G12D, against G12D, ERAS-15 has about a 50% or higher response rate. If that holds, then it sort of reinforces the thesis that ERAS-15 was engineered with two main improvements in mind. So the first was higher potency. So with the 8 to 21-fold higher binding affinity against cyclophylline A, you just create a lot more of these binary complexes that then go hunting for RAS to form a ternary complex and shut RAS off, right? So you're turning it from the on-state to the off-state. So as a result of that CIP-A binding affinity, you have 5 to 10-fold higher potency, both in vitro and in vivo. And it seems to translate in the clinic. Our potential go-forward dose at 32 milligrams is one-tenth of the comparator go-forward dose in pancreatic. So that's one aspect to look at. I think in G12D, if we can maintain that sort of differentiation, the other key engineering feat was optimizing PK with lower clearance, higher oral bioavailability, and longer half-life, and better biodistribution. So, because... ERAS-15 hones in on CYP-A with much higher binding affinity. The CYP-A that's overexpressed in multiple solid tumor types, I think, allows for a potentially wider therapeutic window for ERAS-15. So all of that may explain potential for differentiation across the different alleles, and then another thing to look at is what is that relative to the allele-specific inhibitors like the G12D inhibitors that have shown response rates between 30 to 41 percent? Well, I think how that's explained, our scientific hypothesis is wild-type signaling. So where pan-ras hits not just the mutations but also K, H, and N-ras wild-type, the allele-specific mutations tend to spare K, H, and N-ras. And so that is a potential vulnerability that the allele-specific molecules might have that pan-ras would be intended to address.
Amine Makarim, Analyst — Jefferies
All right, sounds good. So, since you're on the topic, can you also comment on non-sponsored lung cancer, the bar you have for that patient population? And, uh... How many of these patients that you are going to show, we should expect a confirmed response, or what percentage, basically?
Jonathan Lim, CEO
Yeah, so we'll be, across pink and lung, we'll be very transparent about, you know, are the responses confirmed or unconfirmed? If they are unconfirmed, is it because they only had one scan and they're still on therapy, so they have the opportunity to confirm? Or are they unconfirmed because they stopped treatment and so they have no opportunity to confirm? So we'll be very transparent about that. I think in an ideal case, you know, if patients are responding rapidly and have had at least two or more scans, then there would be an opportunity for them to confirm. So, in non-small cell lung, we've said the bar is, you know, 10 percentage points of differentiation. We've also said that if you just look at the history of targeted therapy against G12X, some of the next-gen G12C inhibitors, like DivaRacib, for instance, in the Phase I setting, showed objective response rates in the 56% to 59% range. And that's against a mutation that KOLs have told us is more sensitive than the non-G12C mutation. So what we said is that if we can meet or exceed that bar set by Diva-Rasiv, then we'll be feeling good about entering next year where we want to start one potentially registration-enabling trial in the first half of next year in second line plus non-small cell lung that's in RAS mutated. And then starting in the second half of next year, we want to be able to move towards a phase three in first line RAS mutant lung, and that's with PEMBRO. And then if we are able to have a well-tolerated combination of ERAS-15 with PEMBRO, then we also have the option to layer on chemo on top of that. And if we decide to layer on chemo, then that could be a phase 3 trial that starts in the first half of 28.
Amine Makarim, Analyst — Jefferies
So since you're on the topic, maybe let's talk about this safety data that you are going to show. What do you think would be the bar to be differentiated versus the exon-resif? Some of the safety talks is probably on target, but maybe talk about the ones that you think could be on target. Or maybe the GI tax could be off target, if you can elaborate on that.
Jonathan Lim, CEO
Yeah, so in terms of safety tolerability, what we've shown in the April and July data sets that are all publicly available are numerically lower frequency and severity of rash, GI, and stomatitis. And then the so what there is, how does that translate into patients receiving the intended dose for a durable period of time? And that's where interruptions, those reductions, as well as those discontinuations becomes really important. You know, with all the caveats of cross-trial comparisons and lack of head-to-head studies, but I know everyone's always trying to compare our data against Dirac's, but what we did show in July and April was substantially reduced interruptions and reductions and discontinuations, although, to be fair, the discontinuation rate for Dirac's is only 1.2 percent. But on the interruptions, it's about 56% at the 300 milligram dose, and then reductions are about 36%. So if we can substantially reduce that by more than half, then I think that'll be a really good place to be because you really want to keep your foot on the gas in terms of RAS inhibition, and that translates into hopefully more durable responses, especially when you're looking at earlier lines of treatment like first-line pancreatic cancer.
Amine Makarim, Analyst — Jefferies
Just moving on to your phase three strategies, let's talk about the frontline PDAC. What does EURAS-15 need to show to compare with Remed in frontline PDAC in terms of the efficacy and tolerability and combinability with different regiments?
Jonathan Lim, CEO
Yeah, well, I think in terms of efficacy, if we can show that in the second line plus setting that there is a meaningful differentiation on efficacy and safety tolerability, that should translate pretty well in the earlier line of treatment where the bar for safety tolerability especially is higher. So it's hard to say until we actually have tested 15 in the first-line setting what that could be, but you could just imagine that experience in this space is that pan-ras inhibitors that move towards earlier lines of treatment achieve higher overall, you know, objective response rates, and so we would expect for this class of compounds a similar phenomenon where when you start to test it in earlier lines of treatment, The response rates and durability should go up. Now, I think the key for combinability with chemo is can you maintain dose with less down-dosing than what's been observed in combination with chemo with the predecessor compound. So that's something we'll be looking at is what is the safety tolerability as a monotherapy, and then when we combine it with chemo, are we able to hold dose with less down-dosing? If so, that should translate into...
Amine Makarim, Analyst — Jefferies
All right. And maybe talk about your PRMT-5 strategy here. You have now two partners, Tango and BMS, as of now. What's the strategy for this combination? What would be the ideal combination out of this? Does the drug-drug interaction? Count it as a negative or a surprise positive. Do you expect to see a DDI with these combinations, if you can elaborate?
David Chacko, CFO
Yeah, so we just announced yesterday evening a collaboration with BMS for NABLI metastat, their PRMT5 inhibitor, and we had previously announced a collaboration with Tango for Vopi metastat. The nature of these two studies is that in both cases, the other party, meaning Tango and BMS, are sponsoring the study, And we're providing them with drug to run the study. We do think that this is obviously a very important combination, particularly in PDAC, where about 25 to 40 percent of patients have this MTAP deletion where the PRMT5 would be particularly relevant. As you alluded to, I think there's two main axes of differentiation, at least right now, in terms of one being CNS One is penetrant or not, the other being DDI or not, and we're excited to be partnering with both of these players, Tango and Bristol, just given where they are in the space. In terms of your question about whether there would be a DDI or not, we anticipate that just as Dirac's did reduce their dose from 300 to 100 when in combination with Vopey, that That would actually be similar for us as well, that we would likely need to have a reduction as well. I think in the case of just how much it has reduced the dose load in the GI tract, it has shown meaningful improvements in the GI rate for the comparator compound. But given our GI profile actually looks pretty good as a monotherapy, I think the level of reduction in that, we just have less. issue from a GI standpoint to begin with. But we do think, again, that this is a really important combination.
Amine Makarim, Analyst — Jefferies
All right. And maybe if we can talk about the CRC strategy right now. So what are the plans to expand into the CRC? You are doing a combination. Where does that stand? And when should we see the data for combining there?
Jonathan Lim, CEO
Yeah, well, first of all, we're excited that ERAS-15 is the first pan-ras molecule to be able to have an active dose combined successfully with an anti-EGFR antibody. I think when you look at a disease like CRC that's so highly addicted to the MAP kinase pathway, you really need to have an answer for EGFR where reactivation of the pathway really happens through EGFR. So you get adaptive resistance where you could hit RAS really hard, but EGFR is an escape valve that can reactivate the pathway. So you need to be able to combine with an anti-EGFR agent. And we announced earlier this year over the summer that 16 milligrams of ERAS-15 successfully cleared the DLT, a valuable period, with no DLTs in combination with full-dose panatumumab. So at the time, we said we were expanding that cohort while also exploring 24 milligrams of ERAS-15 with panetumumab. So our guidance is, you know, first half of next year in terms of data from that, so stay tuned.
Amine Makarim, Analyst — Jefferies
All right. A lot to discuss, but very limited time. I want to switch gears to 4001. You have an update coming up by the end of the year. So can you tell us – What should we expect in terms of the number of patients, how long have these patients followed, and is this going to be primarily those escalation patients?
David Chacko, CFO
Yeah, so Borealis 1 is our phase 1 study for ERAS-4001, the pan-K-RAS inhibitor. This is a dose escalation, and so you can expect what you would expect from a typical dose escalation. It's going to be primarily focused around safety, tolerability, PK, initial signs of activity, and we've guided to this being dozens of patients. I think I answered all your questions.
Amine Makarim, Analyst — Jefferies
Yes. Yeah. Will there be enough patients across PDAC, lung, and CRC to show how the drug works across these three indications?
David Chacko, CFO
So think of this as being, again, a phase one dose escalation where it's an all-comer study as long as the patient has a KRAS mutation, and the goal of it is to try to get to a dose and understand the PK and tolerability and some of the other aspects, and so it's not so much about identifying particular tumor types but about, you know, some of those other considerations.
Amine Makarim, Analyst — Jefferies
And where do you see a PAN-K-RAS can fit best in this land escape, given PAN-RAS is already expanding massively in PDAC and subsequently long?
David Chacko, CFO
It's a great question. The way that we think about the pan-KRAS space is that, especially given the data that we've shown with 0015, our pan-RAS inhibitor, is that one avenue for 4001 is its combination potential with 0015. So, as Jonathan was mentioning earlier, 0015, the pan-RAS inhibitor, works through two mechanisms, one of which is to cause downstream effector blockade. The other is to cause hydrolysis of the RAS protein from the GTP state to the GDP state. And then 4001, which has preferential activity against the GDP inactive state, you put those two together, and it's kind of that one-two punch in terms of hitting RAS in both the GTP and the GDP state. So we think that that's a really interesting combination that we are uniquely positioned to be able to advance, given that we have both of those in-house.
Amine Makarim, Analyst — Jefferies
And do you think that... What's your expectation on safety there when combining these two drugs, or do you think it's going to be additive, or not so much on, let's say, the rash and GI tugs?
David Chacko, CFO
Yeah, so we'll have to see what that looks like. I mean, so just looking broadly at what has been disclosed in the pan-KRAS space, which isn't much, the theory behind a pan-KRAS is that by sparing H and NRAS that you should have a better rash profile, and so that should potentially help. Now, that said, we do believe that our pan-ras rash profile is actually improved relative to the predecessor compound. The question is, do you also have GI toxicity with the pan-K-ras? Again, our GI profile for our pan-ras is also improved relative to the predecessor compound, and so the question is, when we put those together, what does that look like? We won't know until we actually put them together, but we believe that that could be a good combination Thank you.
Amine Makarim, Analyst — Jefferies
All right. This has been a great conversation.
David Chacko, CFO
Thank you very much for joining us.
Jonathan Lim, CEO
Thank you.